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Abstract
Background: The purpose of this study was to examine the effects of glucose reduction stress on lymphoblastic cell line (LCL)
gene expression in subjects with schizophrenia compared to non-psychotic relatives.
Methods: LCLs were grown under two glucose conditions to measure the effects of glucose reduction stress on exon
expression in subjects with schizophrenia compared to unaffected family member controls. A second aim of this project was to
identify cis-regulated transcripts associated with diagnosis.
Results: There were a total of 122 transcripts with significant diagnosis by probeset interaction effects and 328 transcripts with
glucose deprivation by probeset interaction probeset effects after corrections for multiple comparisons. There were 8
transcripts with expression significantly affected by the interaction between diagnosis and glucose deprivation and probeset after
correction for multiple comparisons. The overall validation rate by qPCR of 13 diagnosis effect genes identified through
microarray was 62%, and all genes tested by qPCR showed concordant up- or down-regulation by qPCR and microarray. We
assessed brain gene expression of five genes found to be altered by diagnosis and glucose deprivation in LCLs and found a
significant decrease in expression of one gene, glutaminase, in the dorsolateral prefrontal cortex (DLPFC). One SNP with
previously identified regulation by a 3' UTR SNP was found to influence IRF5 expression in both brain and lymphocytes. The
relationship between the 3' UTR rs10954213 genotype and IRF5 expression was significant in LCLs (p = 0.0001), DLPFC (p =
0.007), and anterior cingulate cortex (p = 0.002).
Conclusion: Experimental manipulation of cells lines from subjects with schizophrenia may be a useful approach to explore
stress related gene expression alterations in schizophrenia and to identify SNP variants associated with gene expression.
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Background
Microarray studies in postmortem brains of subjects with
schizophrenia have implicated altered gene expression in
pathways involved in myelination [1], GABAergic and
glutamatergic transmission [2,3], synaptic plasticity [4,5]
and metabolic pathways [6-8] [for review see [9]]. While
examining gene expression in brain tissue from subjects
with psychiatric or neurological disorders might be more
relevant to disease pathology, assessment of whole blood
or lymphocyte gene expression has several advantages,
including practical availability of blood compared to
brain tissue in human subjects and reduced confounds
such as post-mortem interval (PMI), pH and agonal fac-
tors.
A number of studies have demonstrated the utility of
using whole blood [10-12], transformed lymphocytes
[3,6,13], peripheral blood mononuclear cells [14-17], and
peripheral blood cells [18] as biomarkers in psychiatric
and neurological disorders. These studies, while employ-
ing a variety of cell types, have been used to study panic
disorder, nicotine dependence, post-traumatic stress dis-
order [15], schizophrenia [3,6,10,18], bipolar disorder
[10], Huntington disease [11], epilepsy [12], Tourette syn-
drome [12], Down syndrome and Alzheimer's disease
[13,16]. In addition to increased availability of lym-
phocytes and reduced confounds such as PMI, pH and
agonal factors, transformed lymphocytes have the advan-
tage of being more readily amenable to experimental
manipulations than postmortem brain tissue. While it
may be argued that state-dependent and brain tissue-
dependent features are avoided by use of the cell lines,
more stable genetic features may be prominent. Further-
more, previous work found a moderate correlation
between blood and gene expression from 17 brain regions
in humans, and reported that about half of a predeter-
mined set of candidate genes relevant to schizophrenia
were expressed in both whole blood and prefrontal cortex
[19]. Experimental manipulation of cell lines from sub-
jects with schizophrenia may be a useful approach to
explore stress related gene expression alterations in schiz-
ophrenia and to identify SNP variants associated with
gene expression. The purpose of this study was to examine
the effects of glucose reduction stress on LCL gene expres-
sion in subjects with schizophrenia compared to non-psy-
chotic relatives.
Recently, Naydenov et al (2007) [20] examined the effects
of glucose deprivation in lymphocytes to study stress-
induced changes in gene expression in bipolar disorder
compared to controls. Naydenov et al (2007) [20]
reported significant differences between subjects with
bipolar disorder and controls in expression of genes
related to the mitochondrial respiratory chain. This study
demonstrated the advantages of combining a cellular
model with experimental manipulation of glucose depri-
vation, which identified gene expression that was blunted
in bipolar disorder but not controls.
The neural diathesis-stress model of schizophrenia pro-
poses that in vulnerable individuals, psychosis can be trig-
gered or worsened by stress and the interaction of stress
with the dopamine system [21]. In addition to psychoso-
cial stressors, metabolic stressors may also influence
dopamine and stress responses. Previous work has also
shown an increased dopamine response [22] and HPA
activation [23] in subjects with schizophrenia compared
to controls following metabolic stress due to 2-deoxyglu-
cose treatment, although the molecular basis for this dif-
ferential response is not understood. In the present study,
it was hypothesized that a subset of genes would respond
differentially to environmental manipulation (glucose
reduction) in individuals with schizophrenia compared to
controls.
Affymetrix 1.0 ST human exon arrays were utilized for this
study to interrogate exon-level expression across the entire
transcriptome. Exon arrays differ significantly from 3'
expression arrays in the number and placement of the oli-
gonucleotide probes and in the design of control probes
for background correction. The Affymetrix 1.0 ST human
exon array contains more than 5 million 25 bp oligomer
probes, forming 1.4 million probe sets that together inter-
rogate 1 million known and predicted exons up to four
probes are selected from each putative exonic region. The
coverage of the human 1.0 exon array represents over a 4-
fold increase in probe density and an 8-fold increase in
the number of perfect-match targets compared to the
human U133 Plus 2.0 array. One advantage of the human
1.0 exon array platform is more robust measurements at
the transcript level due to increased number of probes per
transcript (30-40 probes across each entire RefSeq tran-
script compared to 11 probes mostly at the 3' transcript
end in the U133 array). The probe sets are distributed
along the entire length of the gene (as opposed to a con-
centration at the 3' end) allowing the potential to distin-
guish between different isoforms of a gene at the level of
individual exons [24]. Therefore, this platform may iden-
tify alternative splicing events, which might play an
important role in the pathophysiology of schizophrenia.
Exon arrays have been demonstrated to attain improved
sensitivity and specificity of absence/presence calls and
may allow more accurate quantitative measurement of the
level of gene expression compared to traditional 3' based
arrays [25]. Quantitative real time PCR was used to vali-
date exon array findings for 13 genes in lymphocyte sam-
ples. A subset of the validated genes was then assessed in
brain samples from a separate cohort of subjects. Rese-
quencing and TaqMan genotyping assays were conducted
on one gene selected from exon array results in a largerBMC Medical Genomics 2009, 2:62 http://www.biomedcentral.com/1755-8794/2/62
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cohort to identify gene variants associated with altered
expression.
Methods
Subjects
Three cohorts were selected for this case-control study.
Cohort 1 was used in the exon array analysis and con-
sisted of LCLs from ten male subjects (five subjects with
schizophrenia and five related non-psychotic subjects
analyzed under normal and glucose deprivation condi-
tions) for a total of 20 exon arrays (Table 1). The average
age of controls and subjects with schizophrenia was 45
and 42, respectively. Cohort 2 was used for TaqMan gen-
otyping assays on a total of 541 subjects (111 subjects
with bipolar disorder, 19 subjects with major depressive
disorder, 172 subjects with schizophrenia and 239 con-
trols). Cohort 3 consisted of mRNA samples from two
brain regions, dorsolateral prefrontal cortex (DLPFC) and
anterior cingulate (AnCg), from 112 subjects, schizophre-
nia (n = 15), bipolar disorder (n = 17), major depressive
disorder (n = 33) and controls (n = 47). Subjects with
bipolar disorder and major depressive disorder were
included in the analysis to test for the specificity of find-
ings to schizophrenia. All three cohorts were obtained
with IRB approval at the University of California, Irvine
and cohorts 1 and 2 were obtained with IRB approval in
Costa Rica. In cohort 3, 60 subjects were also genotyped
(Table 2). Written, informed consent was obtained from
all the individuals or from the surviving next-of-kin for all
blood and brain samples reported in this study. Both
cohorts 1 and 2 samples were collected from the Central
Valley of Costa Rica in a relatively isolated population
[26], and cohort 3 was collected in Southern California.
Ficoll extraction and Epstein-Barr virus transformation
Approximately 10 mL of blood was centrifuged at 1500
rpm for 10 min at RT (25°C). The upper layer was trans-
ferred to a 15 ml Falcon tube containing 5 ml Ficoll-Paque
Plus (GE Healthcare, Piscataway, NJ) and centrifuged for
20 min at 2500 rpm at RT. The buffy coat layer was trans-
ferred to a new tube containing 10 ml of 1.0 M PBS (pH =
7.4) and centrifuged at 1000 rpm for 10 min at RT. The
pellet was resuspended in 400 μl of supernatant and an
equal volume was added to two wells of a culture plate.
One ml of concentrated Epstein-Barr virus stock was
added to each plate well and the plate was incubated for
45 min at 5% CO2 and 37°C. Next, 10 μl of phytohae-
magglutinin (PHA) was added to each well and 400 μl of
transforming media RPMI 1640 containing 15% fetal
bovine serum, 2 mM glutamine and 25 mg of gentamicin.
The cell lines were grown until confluent and then stored
frozen in RPMI supplemented media and 10% dimethyl-
sulphoxide (DMSO) until being grown for the experi-
ment.
Glucose deprivation of lymphoblastoid cell lines
LCLs from cohort 1 subjects were grown under two envi-
ronmental conditions (glucose deprived and normal glu-
cose) to measure the effects of stress on exon expression
and to examine state and trait-dependent alterations in
exon expression in schizophrenia. All cell lines were
thawed on the same date and grown with the same batch
of RPMI-1640 supplemented media at 5% CO2 and 37°C
to approximately the same cell density of 107 cells in a 25-
cm2 flask. The cells from the 25-cm2 flask were split into
two separate 75-cm2 flasks and grown to a confluency of
approximately 5×107 cells/flask. One flask from each sub-
ject was left to grow in normal glucose (2%) while the
other flask of cells was transferred into complete media
containing 5.55 mM d-glucose for 24 hours. These cells
were then placed into low glucose media containing 2.77
mM d-glucose (0.5%) for 48 hours. Microscopic cell death
was not apparent when cell counts were taken using
trypan blue stain.
Brain and lymphoblastoid cell line RNA extraction
Coronal slices of the brain were rapidly frozen on pre-
cooled (to -120°C) aluminum plates, and stored at -
80°C. The DLPFC and AnCg were later dissected and total
RNA was extracted separately from each sample with TRI-
Table 1: Lymphoblastoid cell lines (LCLs) from ten subjects were grown under normal conditions or under glucose deprivation.
Diagnosis Relationship Pair Age RIN
(Normal Glucose)
RIN
(Glucose Deprivation)
28S/18S 
(Normal Glucose)
28S/18S
(Glucose Deprivation)
Schizophrenia Brothers 1 43 9.8 10.0 2.0 1.7
Unaffected Brothers 1 53 10.0 10.0 1.6 1.7
Schizophrenia Brothers 2 48 9.5 10.0 1.6 1.9
Unaffected Brothers 2 32 9.1 9.9 2.0 1.6
Schizophrenia Brothers 3 45 9.6 9.6 1.6 1.5
Unaffected Brothers 3 46 9.6 8.6 2.0 1.6
Schizophrenia Uncle 4 33 10 10.0 1.9 1.7
Unaffected Nephew 4 22 9.9 10.0 1.5 1.7
Schizophrenia Cousins 5 47 9.4 10.0 1.7 1.5
Unaffected Cousins 5 63 9.6 9.8 1.7 1.6
LCLs (N = 20) for five pairs of age- and sex- matched subjects before and after glucose deprivation were assayed by exon array. RNA quality was 
assessed by Agilent prior to exon array and all samples were found to have acceptable 28S/18S ratios and RNA Integrity Numbers (RIN).BMC Medical Genomics 2009, 2:62 http://www.biomedcentral.com/1755-8794/2/62
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zol Reagent (Invitrogen, Carlsbad, CA) according to the
supplier's protocol. Briefly, 1 ml of TRIzol was added to 5-
10×106 cell pellets [10 ml of TRIzol per 50 ml confluent
T75 flask of cells (pelleted)] or 50 mg DLPFC tissue. All
final RNA pellets were resuspended in 100 μl of diethyl
pyrocarbonate (DEPC) treated water. RNA degradation
was assessed by quantifying the resulting 28S and 18S
ribosomal band peak height ratios using the Agilent Bio-
analyzer 2100 (Agilent, Palo Alto, CA) (see Tables 1 and
2).
Affymetrix Human Exon 1.0 ST Array
The Affymetrix Human Gene Chip Exon 1.0 ST Array
interrogates over one million exons representing over
17,868 NCBI Reference Sequence (RefSeq) transcripts.
Arrays were run using the manufacturer's technical proto-
col (Affymetrix, Santa Clara, CA). Briefly, 2 μg total RNA
was subjected to a ribosomal RNA removal procedure
(RiboMinus Human/Mouse Transcriptome Isolation Kit,
Invitrogen) to reduce the 28S and 18S rRNA population in
order to minimize background and increase sensitivity of
the assay. Reduced RNA was then reverse-transcribed to
cDNA using random hexamers tagged with a T7 promoter
sequence followed by a second strand cDNA synthesis
using DNA polymerase (GeneChip WT cDNA Synthesis
Kit, Affymetrix). The resulting double stranded cDNA was
then used for amplification of antisense cRNA and
cleaned using the Gene Chip Sample Cleanup Module
(Affymetrix). A second cycle cDNA synthesis was then per-
formed using random primers to reverse transcribe the
cRNA into sense single stranded DNA which was then
fragmented, labeled, and hybridized to Affymetrix
Human Gene Chip Exon 1.0 ST Arrays. Arrays were
washed, stained, and scanned on the Affymetrix Fluidics
Station and G7 Affymetrix high-resolution scanner using
GCOS 1.3. Gene expression traits were derived from the
cel files and analyzed with a Robust multi-array average
(RMA) procedure [27].
Quantitative polymerase chain reaction (qPCR) of 
candidate diagnosis genes
The 100 μl reverse transcription reaction consisted of
RNase-free water, TaqMan reverse transcriptase buffer (10
μl), 25 mM MgCl2 (22 μl), dNTPs (20 μl), Oligo d(T)16 (5
μl), RNase inhibitor (2 μl), MultiScribe Reverse Tran-
scriptase, and 2 μg RNA from brain or lymphocytes. Real-
time PCR was performed using the ABI Prism 7000
Sequence Detection System®  (Applied Biosystems™),
using the default thermal cycler program for all genes: 10
min of pre-incubation at 95°C followed by 40 cycles for
15 sec at 95°C and 1 min at 60°C. Individual real-time
PCR reactions were carried out in a volume of 25 μl in 96-
well plates (Applied Biosystems™) containing 12.5 μl
SYBR Green, 5 μl cDNA (4 ng/μl), and 7.5 μl H2O. At the
end of each reaction, the cycle threshold (Ct) was manu-
ally set at the level that reflected the best kinetic PCR
parameters. Although each RNA sample was either DNase
treated or Qiagen column purified, to further increase
gene specificity one primer in each pair was designed
(Primer Express, ABI) to span two exons and primers were
not 3' UTR biased. The primers were tested for amplifica-
tion of any residual genomic DNA contamination. The
dissociation curves of real time PCR were monitored for
primer-dimer pairings, which interfere with SybrGreen
fluorescence measurements. A melting curve analysis was
used for all primers and any primers that displayed ampli-
fication of genomic DNA less than 35 Ct were discarded
and redesigned. (See Additional File 1 for primer
sequences.)
TaqMan SNP genotyping
DNA samples were genotyped for an IRF5 variant
(rs10954213) using TaqMan 5'-allele discrimination
assays (Applied Biosystems, Foster City, CA). Allele-spe-
cific probes were labeled with the fluorescent dyes VIC
and FAM, respectively. The PCR reaction was carried out
in a total reaction of 5 μl (1 μl DNA, 2.5 μl TaqMan master
mix, 0.125 μl 40× a IRF5 assay, 1.375 μl H2O) using the
following amplification protocol: denaturation at 95° for
10 minutes, followed by 50 cycles at 92° for 15 seconds
and at 58°C for 1.5 minutes. The genotype of each sample
was determined by measuring allelic-specific fluorescence
using the automated ABI Prism 7900 Sequence Detection
system, with SDS 2.3 software for allelic discrimination
(Applied Biosystems). Duplicate samples and negative
controls were included to check the accuracy of genotyp-
ing.
Table 2: The dorsolateral prefrontal cortex (DLPFC) and anterior cingulate (AnCg) were dissected and RNA extracted from a total of 
60 subjects.
Diagnosis N DLPFC 28S/18S 
(Mean ± S.D.)
AnCg 28S/18S 
(Mean ± S.D.)
DLPFC RIN (Mean ± S.D.) DLPFC RIN (Mean ± S.D.)
BPD 7 2.26 ± 0.36 2.08 ± 0.38 7.87 ± 0.38 8.09 ± 0.65
Control 27 2.33 ± 0.46 2.11 ± 0.36 7.95 ± 0.31 8.04 ± 0.80
MDD 15 2.21 ± 0.32 2.02 ± 0.31 7.76 ± 0.53 8.01 ± 0.57
SZ 11 2.00 ± 0.43 1.90 ± 0.39 7.63 ± 0.80 8.36 ± 0.55
RNA quality was assessed prior to exon array and all samples were found to have acceptable 28S/18S ratios.BMC Medical Genomics 2009, 2:62 http://www.biomedcentral.com/1755-8794/2/62
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Identification of SNPs associated with candidate gene 
expression
A second aim of this project was to identify cis-regulated
transcripts associated with diagnosis. The mRNA by SNP
Browser v 1.0.1 software was used to identify SNPs within
the interferon regulatory factor 5 (IRF5) that were strongly
related to expression and the regions around these SNPs
were sequenced in subjects with exon array data. The
mRNA by SNP Browser software [28-30] contains associa-
tion results of 54,675 transcripts with 406,912 SNPs (p <
0.05) and allows SNPs to be visualized in their genomic
context along with linkage disequilibrium maps and puta-
tive haplotype blocks derived from the analysis of over 3
million SNPs genotyped in several populations by the
International HapMap project. The IRF5 SNP with the
most significant p-value related to expression in cohort 1
was followed up to examine whether there was an associ-
ation between genotype and diagnosis in cohort 2, and
genotype and expression in cohort 3.
Data analysis
Data were analyzed in Partek Genomic Solutions (St.
Louis, MO) by a repeated measure ANOVA (mixed
model) with Diagnosis × Probeset, Glucose deprivation ×
Probeset, Diagnosis × Probeset as main effects and corre-
sponding interactions. Transcript expression was esti-
mated by an average of the expression levels across all
probesets in each RefSeq transcript. Probeset effects were
examined to identify exon specific effects of diagnosis or
glucose deprivation. The threshold for significance was
obtained using a Benjamini-Hochberg step-down FDR
cutoff of 25%.
Ingenuity pathway analysis
Genes with a step-down FDR less than or equal to 25%
were used as the input variables for the data set to query
the Ingenuity Pathways Analysis (IPA) software v7.1
canonical pathway analysis. Gene symbols were mapped
to corresponding gene objects in the Ingenuity Pathways
Knowledge Base. Each network or pathway was set to have
a maximum of 35 focus genes and IPA identified those
pathways that were most significant to the input data set.
The significance of the association between the data set
and the canonical pathway was determined based on the
Benjamini-Hochberg step-down FDR calculated with the
Fisher's exact test by calculating the probably that the
association between the genes in the data set and the
canonical pathway is due to chance alone.
Results
We tested the effects of glucose deprivation on LCL tran-
script profiles in subjects with schizophrenia compared to
non-affected relatives. Diagnosis and glucose deprivation
by probeset interaction effects were examined to identify
exon-specific changes in expression. Transcripts were
identified with significantly altered expression using an
FDR cut-off of 25%. This cut-off was chosen based upon
previous work by Benes et al, 2006 [31], which suggests an
FDR cutoff of 5% may be too stringent for pathway anal-
yses. There were no overall effects of diagnosis using a
step-down FDR (Benjamini-Hochberg) cutoff of 25%.
Step-down FDR is more conservative than step-up FDR
and gives similar numbers of findings compared to Bon-
ferroni correction [32]. Using a Benjamini-Hochberg step-
down FDR cutoff of 25% there were 122 significant Diag-
nosis × Probeset effects, 328 Glucose deprivation ×
Probeset effects and 8 Diagnosis × Glucose deprivation ×
Probeset effects (see Additional file 2 for further detail; see
Figures 1, 2 and 3 and Additional file 3 for exon array
expression levels of representative genes GLS, DSC2 and
ERO1L). Bonferroni correction of the mixed model
ANOVA results was initially considered, but this approach
assumed independent relationship among transcripts and
these assumptions would be violated. Nevertheless, with
a Bonferroni correction of 5%, no overall diagnosis
effects, 72 Diagnosis × Probeset effects, 222 Glucose dep-
rivation × Probesets effects and 5 Diagnosis × Glucose
deprivation × Probeset effects were significant.
QPCR validation of top ranked genes in cohort 1
Thirteen candidate genes were chosen for qPCR validation
based on p-value and fold-change of probesets with
altered expression between schizophrenic and non-psy-
chotic relatives' cell lines. Eight of 13 schizophrenia can-
didate genes were validated by qPCR (Table 3) for an
overall validation rate by qPCR of 62% (p < 0.05, two
tailed t-test) while the remaining 5 genes showed a trend
for validation by qPCR (p < 0.1, two tailed t-test). All
qPCR results were concordant compared to microarray in
terms of the direction of fold changes. The exon array
expression of three genes validated by qPCR (GLS, ERO1L
and DSC2) is shown in Figures 1, 2 and 3).
Ingenuity pathway analysis
Ingenuity pathway analysis was conducted using all tran-
scripts with p-values below a Benjamini-Hochberg step-
down FDR cutoff of 25%. For the 8 Diagnosis × Glucose
deprivation × Probeset effect genes, IPA identified a net-
work involving the transcription factor HFN4A, which
was associated with disease specific responses to glucose
deprivation. To increase the number of genes for an
exploratory analysis, we examined a larger set of 67 Diag-
nosis × Glucose deprivation × Probeset effect genes iden-
tified by step-up FDR cutoff of 25% and a larger network
involving transcription factor HFN4A was identified (see
Figure 4). The three most significant functional categories
were molecular transport, protein trafficking, and cellular
function and maintenance (p < 0.05). The 122 genes with
significant Diagnosis × Probeset effects based on a Ben-
jamini-Hochberg step-down FDR cutoff of 25% wereBMC Medical Genomics 2009, 2:62 http://www.biomedcentral.com/1755-8794/2/62
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(a) A significant Diagnosis × Glucose deprivation × Probeset interaction effect on GLS expression was detected by exon array Figure 1
(a) A significant Diagnosis × Glucose deprivation × Probeset interaction effect on GLS expression was 
detected by exon array. Exon array probeset expression levels are shown for the entire transcript. The probe set number 
is shown on the x-axis and the average expression for each diagnosis group is depicted on the y-axis. There was a significant 
decrease in probeset expression in subjects with schizophrenia (shown in blue) compared to controls (shown in red), under 
normal glucose conditions (b) The probeset with the most significant Diagnosis × Glucose interaction was probeset 2520346 
(p = 0.001). Posthoc analysis revealed a significant decrease in GLS probeset expression in subjects with schizophrenia before 
and after glucose deprivation compared to normal controls (p = 0.001 and 0.0002, respectively).






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A significant Diagnosis × Glucose deprivation × Probeset interaction effect on DSC2 expression was detected by exon array Figure 2
A significant Diagnosis × Glucose deprivation × Probeset interaction effect on DSC2 expression was detected 
by exon array. (a) Exon array probeset expression levels are shown for the entire transcript. The probe set number is shown 
on the x-axis and the average expression for each diagnosis group is depicted on the y-axis. The probe set number is shown on 
the x-axis, and the average expression for each diagnosis group is depicted on the y-axis. There was a significant Diagnosis × 
Probeset interaction effect on DSC2 expression, with a significant decrease in DSC2 expression in subjects with schizophrenia 
(shown in blue) compared to controls (shown in red). (b) The DSC2 probeset with the most significant diagnosis effect was 
probeset 3803005 (p = 2.06 × 10-5) and is depicted by dot plot. These findings were validated by qPCR (p = 0.0038).


A 
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A significant Diagnosis × Glucose deprivation × Probeset interaction effect on ERO1L expression was detected by exon array Figure 3
A significant Diagnosis × Glucose deprivation × Probeset interaction effect on ERO1L expression was detected 
by exon array. (a) Exon array probeset expression levels are shown for the entire transcript. The probe set number is shown 
on the x-axis and the average expression for each diagnosis group is depicted on the y-axis. There was a significant Diagnosis × 
Probeset interaction effect on ERO1L expression, with a significant decrease in ERO1L expression in subjects with schizophre-
nia (shown in blue) compared to controls (shown in red). (b) The probeset with the most significant diagnosis effect was 
probeset 3564812 (p = 0.0025) and is depicted by dot plot. These findings were validated by qPCR (p = 0.0037).


A
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associated with no significant over-represented functional
categories. A gene network of significant diagnosis effect
genes is shown in Figure 5. The network includes 22 genes
that showed diagnosis effects on gene expression. Cal-
modulin was a central complex located within this net-
work. There were no over-represented functional
categories for the 328 genes with significant Glucose dep-
rivation × Probeset effects based on a Benjamini-Hoch-
berg step-down FDR cutoff of 25%. There was not an over-
representation of diagnosis-related genes implicated in
schizophrenia.
Resequencing to identify variants associated with altered 
gene expression in schizophrenia
A second aim of this study was to identify cis-regulated
transcripts that were altered in schizophrenia to investi-
gate gene variants that might be associated with genetic
risk for schizophrenia. For all genes validated by qPCR,
SNPs associated with expression were identified using the
mRNA by SNP Browser [28-30]. SNPs with highly signifi-
cant LOD scores associated with expression of IRF5 were
identified within the IRF5 gene using the mRNA by SNP
Browser, but not for other Diagnosis × Probeset effect
genes that were validated by qPCR (Table 4). Regions
(~300 bps) around SNPs of interest [33] were rese-
quenced in 10 subjects from cohort 1. Two SNPs of inter-
est (rs4728142 and rs10488630) adjacent to exon array
probeset 3023264 showed a significant association
between genotypes (G and A alleles, respectively) and
increased microarray expression of IRF5 (Table 5). These
SNPs showed high linkage disequilibrium. Three addi-
tional SNPs not listed in the mRNA by SNP Browser soft-
ware (rs11770589, rs10954214 and rs10954213) were
identified within IRF5 probe set 3023264 by re-sequenc-
ing. These SNPs were included in our analysis because of
their proximity to SNPs shown to be associated IRF5
expression. There was a significant effect of genotype of
SNPs rs4728142, rs10954214 and rs10954213 on IRF5
expression in cohort 1 LCLs (Table 5).
SNP rs10954213 association with IRF5 expression in 
cohorts 2 and 3
TaqMan SNP genotyping was performed for IRF5 SNP
rs10954213 on DNA extracted from lymphocyte from
541 individuals (cohort 2) and brain samples from 60
individuals (cohort 3). This SNP was selected because it
was the most significantly associated with expression in
our study and was also previously shown to be associated
with expression [33]. Cohorts 2 and 3 included subjects
with bipolar disorder and major depressive disorder in
addition to subjects with schizophrenia and controls to
investigate the specificity of an association of the geno-
type with schizophrenia.
The association of the rs10954213 SNP was also investi-
gated in a larger sample of subjects (cohort 2, N = 541)
with schizophrenia, bipolar disorder and major depres-
sive disorder. There was no significant association
between diagnosis and this IRF5 SNP (chi-square = 0.26,
p = 0.99). (See tables 6 and 7 for genotype frequencies
within each cohorts 2 and 3). The genotype frequencies
for each diagnosis group were in Hardy-Weinberg equilib-
rium.
Table 3: QPCR of LCLs was performed to confirm altered gene expression in twelve top schizophrenia candidate genes identified by 
exon array analysis from Diagnosis × Probeset interactions.
Gene
Symbol
Diagnosis 
(p-value)
Glucose 
(p-value)
Diagnosis × 
Glucose (p-
value) 
Mean ΔCt 
(C-GD)
Mean
ΔCt (C-NG)
Mean ΔCt 
(SZ-GD)
Mean ΔCt
(SZ-NG) 
FC
ERO1L 0.0037 0.6354 0.998 -1.45 -1.31 -0.41 -0.26 0.48
DSC2 0.0038 0.5318 0.999 0.18 0.64 2.58 3.03 0.19
MCCC2 0.0057 0.0006 0.713 -2.23 -1.31 -1.53 -0.76 0.65
CR1 0.0068 0.4561 0.797 0.72 1.13 2.06 2.26 0.42
IRF5 0.0104 0.9943 0.897 -0.27 -0.21 -1.63 -1.69 2.68
GLS 0.0325 0.9193 0.441 0.515 0.234 -0.756 -0.380 1.93
DSC3 0.0458 0.5623 0.709 4.38 4.62 6.42 7.53 0.18
ADCY1 0.0478 0.0083 0.893 2.34 3.97 3.52 5.00 0.46
PPFIBP1 0.0630 0.1272 0.746 1.83 2.54 2.69 3.16 0.60
PDE4D 0.0788 0.2563 0.691 2.81 3.66 4.03 4.44 0.50
ZC3HAV1 0.0975 0.9714 0.922 -0.07 -0.03 1.18 1.09 0.44
TNIK 0.1037 0.0390 0.950 0.86 2.21 1.90 3.18 0.50
HEBP2 0.1075 0.7067 0.976 -0.07 0.19 1.15 1.45 0.42
These genes were selected for validation after examining probeset-specific expression for diagnosis related differences. The ΔCt was calculated by 
subtracting the Ct of the gene of interest from the Ct of the housekeeping gene SLC9A1. Fold change was calculated as 2^-(schizophrenia mean -- 
control mean). (C -- Control; SZ -- Schizophrenia; GD -- Glucose deprivation; NG -- Normal glucose; FC -- Fold change). The direction of fold 
change between diagnosis groups using microarray and qPCR data was consistent for 100% of the genes. A total of 62% of attempted validations 
were significant when gene expression was measured by qPCR. Bold data was significant by microarray and qPCR.BMC Medical Genomics 2009, 2:62 http://www.biomedcentral.com/1755-8794/2/62
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IPA analysis of genes with Diagnosis × Glucose deprivation × Probeset effects identified a network of 18 genes Figure 4
IPA analysis of genes with Diagnosis × Glucose deprivation × Probeset effects identified a network of 18 genes. 
Red indicates genes upregulated in schizophrenia in the glucose-deprived condition, green indicates genes down-regulated in 
schizophrenia in the glucose deprived condition, compared to normal controls in the glucose normal condition. White indi-
cates the genes were not part of the dataset file genes. Solid lines indicate direct interactions, while dashed lines indicate indi-
rect interactions. The network shapes are indicative of the molecular class (oval -- transcription regulator; square -- cytokine, 
trapezoid -- transporter; diamond -- enzyme; double circle -- complex/group; circle -- other). The network included 18 genes 
that showed diagnosis-dependent expression alterations following glucose deprivation, with Hepatocyte nuclear factor 4, alpha 
(HNF4A) as one node in this gene network.BMC Medical Genomics 2009, 2:62 http://www.biomedcentral.com/1755-8794/2/62
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IPA analysis of genes with Diagnosis × Probeset effects identified a network of 22 genes Figure 5
IPA analysis of genes with Diagnosis × Probeset effects identified a network of 22 genes. Red indicates genes 
upregulated in schizophrenia, green indicates genes down-regulated in schizophrenia. White indicates the genes were not part 
of the dataset file genes. Solid lines indicate direct interactions, while dashed lines indicate indirect interactions. See Figure 4 
legend for description of molecular classes indicated by each network shape. The network included 22 genes that showed diag-
nosis effects on gene expression. Interestingly, calcium-activated calmodulin, which has previously been shown to be altered in 
expression in schizophrenia [49], was a centrally located complex within this network.BMC Medical Genomics 2009, 2:62 http://www.biomedcentral.com/1755-8794/2/62
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The expression of IRF5 was studied in cohort 3 in the
DLPFC. The relationship between rs10954213 genotype
and IRF5 expression was significant in these subjects in
the DLPFC (F = 11.76; df = 2, 58; p = 8.11 × 10-5) and ante-
rior cingulate cortex (F = 5.55; df = 2, 58; p = 0.007) from
cohort 3 (see Figure 6). However, there were no significant
associations between diagnosis and IRF5 expression in the
DLPFC (F = 0.04; df = 1,59; p = 0.996) or the anterior cin-
gulate (F = 0.28; df = 1,59; p = 0.84), nor Genotype ×
Diagnosis interaction effect on expression in the DLPFC
(F = 0.90; df = 5, 55; p = 0.52) or the anterior cingulate (F
= 0.90; df = 5, 55; p = 0.84).
Brain gene expression of candidate biomarkers
Five additional genes with significantly altered probeset
expression in LCLs between schizophrenia and unaffected
relatives (ADCY1, DSC2, DSC3, GLS and PDE4D) were
examined by qPCR expression in DLPFC tissue from sub-
jects with schizophrenia and non-psychotic controls in
cohort 3. The direction of change of GLS in both LCLs and
the prefrontal cortex was consistent and decreased in
schizophrenia in LCLs under glucose deprivation and the
DLPFC. For comparison, subjects with bipolar disorder
(BPD) and major depressive disorder (MDD) were
included in the analysis. There was a significant decrease
in expression of GLS in subjects with schizophrenia com-
pared to controls (p = 0.04, Fold Change = 0.73), but no
significant alterations of brain gene expression in schizo-
phrenia of any other transcript examined. There were no
significant alterations in brain expression of any of the
other transcripts examined p-values for the in schizophre-
nia (see Table 8), although ADCY1 was down-regulated in
major depressive disorder and bipolar disorder.
Discussion
The results of this study suggest exon arrays in conjunc-
tion with cell lines and brain samples may be a valuable
tool to identify gene expression associated with genotype
in the context of psychiatric disorders. Despite a relatively
small sample of cell lines grown under two different con-
ditions, this study identified eight differentially expressed
transcripts between cases and controls when compared
under two glucose conditions, 328 transcripts with signif-
icant Glucose deprivation × Probeset effects on expres-
sion, and a total of 122 transcripts with significant
Diagnosis × Probeset effects on expression demonstrating
probeset-specific effects of diagnosis and glucose depriva-
tion on expression. These transcripts passed a 25% step-
down Benjamini Hochberg false discovery and the com-
plete dataset is available by request.
Table 4: There was a significant effect of genotype at two SNPs on IRF5 expression according to the mRNA by SNP Browser data which 
supported the investigation of the effects of these SNPs on probeset expression in the present study.
Gene Location Affymetrix Probeset ID SNP Marker Effect Size LOD p-value
IRF5 7q32 205468_s_at rs4728142 -0.521 9.527 3.50E-11
IRF5 7q32 205468_s_at rs10488630 -0.381 4.937 1.90E-06
The top 25 Diagnosis × Probeset transcripts were examined in mRNA by SNP Browser software [28,30,29] to identify SNPs associated with 
candidate gene expression from LCLs. This table lists the SNP associated with each Affymetrix U133 probeset ID, with the associated effect size, 
logarithm of the odds (LOD) score and p-value that were obtained from mRNA by SNP Browser data.
Table 5: Candidate SNPs within probesets were genotyped by 
resequencing and tested for the effect of genotype on exon array 
expression obtained in LCLs.
SNP F-statistic p-value
rs10954213 17.24 0.0001
rs10954214 22.13 0.0004
rs4728142 4.17 0.04
rs11770589 1.21 0.32
rs10488630 0.56 0.47
There was a significant effect of IRF5 SNP genotype on microarray 
expression of the IRF5 probeset 3023264, for 3 of the 5 SNPS tested 
by ANOVA.
Table 6: IRF5 rs10954213 allele and genotype counts are shown 
for Cohort 2.
Rs10954213 Allele Genotype
Group A G AA AG GG
BPD 129 153 33 63 45
C 183 197 44 95 51
MDD 8 6 1 6 0
SZ 100 96 25 50 23
There was no significant relationship between allele and diagnosis 
group in cohort 2. The χ2 statistic for each diagnosis group frequency 
comparison to control group frequency were as follows: BPD -- 0.37, 
p = 0.53; MDD -- 0.42, p = 0.51; SZ -- 0.42; p = 0.51.BMC Medical Genomics 2009, 2:62 http://www.biomedcentral.com/1755-8794/2/62
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There were no significant main effects of diagnosis. This
might be due to the fact analyses were performed using
summarized transcript data and gene transcript expres-
sion was estimated using the mean expression of all
probesets, which for some transcripts could be 50 - 100
probesets. On the other hand, the Glucose deprivation ×
Probeset and Diagnosis × Probeset interaction effects were
based on probeset data summarized at the exon level
which was 4 - 8 probesets. The finding that expression dif-
ferences within closely matched schizophrenia and unaf-
fected relatives are restricted within certain exons of a
transcript is consistent with the alternatively spliced tran-
scripts being an over-represented significant category
between schizophrenia and controls. As the exon array
does not contain junction probes, this conclusion is spec-
ulative, as the exon array would measure both spliced and
unspliced transcripts, and does not actually differentiate
spliced and unspliced transcripts except in situations
where splicing is an all or none occurrence. Over 70% of
human multi-exon genes are alternatively spliced [34].
Also, limited power may have played a role in our lack of
diagnosis or glucose deprivation effects. The effect sizes
detected for 100 most significant diagnosis effects ranged
from 0.05 to 1.19. A power analysis done in G*Power
showed 80% power to detect an effect size of 0.55 [35].
There is a growing body of evidence of glucose metabo-
lism abnormalities in schizophrenia. In a study by Ryan et
al (2003), more than 15% of subjects with schizophrenia
had impaired fasting glucose tolerance [36]. Subjects with
schizophrenia also had higher fasting plasma levels of glu-
cose, insulin and cortisol and were more insulin resistant
than control subjects [36]. There is also evidence for link-
age between enzymes that control glycolysis and schizo-
phrenia, including PFKFB2, a rate limiting enzyme in
glycolysis, and hexokinase, a regulatory enzyme in the
metabolic pathway [37]. Insulin has been shown to
increase the expression of genes that are decreased in the
hippocampus in subjects with schizophrenia in neurob-
lastoma cells [9]. Moreover, glucose administration
improves verbal declarative memory in clozapine-treated
subjects with schizophrenia [38], although the mecha-
nism of action remains unknown. Previous research has
implicated metabolic and mitochondrial genes
[3,7,8,39,40], including ornithine aminotransferase
(OAT) [7] and metabolic enzyme cytosolic malate dehy-
drogenase (MDH1) [3,41] in schizophrenia, which have
Table 7: IRF5 rs10954213 genotype and allele counts are shown 
for Cohort 3.
rs10954213 Allele Genotype
Group A G AA AG GG
BPD 11 7 4 3 2
C4 3 3 1 1 1 2 1 5
MDD 20 10 7 6 2
SZ 14 14 3 8 3
There was no significant relationship between genotype frequency 
and diagnosis group in cohort 3. The Odds ratio (OR) and p-value 
statistic for each diagnosis group frequency comparison to control 
group frequency were as follows: BPD -- OR = 1.13, p = 1.0; MDD -- 
OR = 1.44, p = 0.50; SZ -- OR = 0.72, p = 0.51).
The relationship between IRF5 expression (measured by  qPCR of the 3'-UTR of IRF5 in two regions of brain in cohort  3) and the IRF5 SNP rs10954213 genotype is shown Figure 6
The relationship between IRF5 expression (meas-
ured by qPCR of the 3'-UTR of IRF5 in two regions of 
brain in cohort 3) and the IRF5 SNP rs10954213 gen-
otype is shown. The ΔCt was calculated by subtracting 
from the Ct IRF5 the average Ct of two housekeeping genes 
(SNX16 and TSR1 in the anterior cingulate and SDHA and 
CAMK2A in the dorsolateral prefrontal cortex). A larger 
ΔCt indicates less expression of the target gene. The rela-
tionship between rs10954213 genotype and IRF5 probeset 
3026432 expression was significant in these subjects in the 
DLPFC (F = 11.76; df = 1, 58;p = 8.11 × 10-5) and anterior 
cingulate cortex (F = 5.55; df = 1,58; p = 0.007) from cohort 
2. The fold changes of expression in the anterior cingulate of 
subjects with the AG and GG genotypes compared to those 
with the AA genotypes were 0.52 and 0.50, respectively. The 
fold changes of expression in the anterior cingulate of sub-
jects with the AG and GG genotypes compared to those 
with the AA genotypes were 0.33 and 0.38, respectively. 
Both regions showed a significant down-regulation in sub-
jects with the AA genotype compared to the AG or GG gen-
otype, consistent earlier reports of lower expression of the 
long 3'UTR in subjects carrying G alleles [33].BMC Medical Genomics 2009, 2:62 http://www.biomedcentral.com/1755-8794/2/62
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not been shown to be influenced by cigarette smoking or
antipsychotic treatment. For these reasons, we examined
the effects of glucose deprivation on gene expression in
subjects with schizophrenia compared to controls.
Of the significantly altered transcripts identified in this
study, only GLS showed significant Diagnosis × Probeset,
significant Glucose deprivation × Probeset, and signifi-
cant Diagnosis × Glucose effects. This gene and four other
Diagnosis × Probeset effect genes were selected for further
study in the DLPFC and only GLS was significant in
DLPFC. Glutaminase, which converts glutamine to gluta-
mate, was decreased in expression in glucose-deprived
LCLs and decreased in expression in the DLPFC in sub-
jects with schizophrenia compared to controls. This is in
contrast to previous findings showing increases in glutam-
inase in the thalamus [42] and in DLPFC [43] of subjects
with schizophrenia. In addition to GLS expression being
regulated by cellular environment, the effects of diagnosis
and glucose on expression varied by exon and may be iso-
form-specific. This gene may be worth further association
study by SNP analysis or resequencing. In addition to
glutaminase, there was a significant Diagnosis × Glucose
deprivation × Probeset effect on PPARGC1B expression.
PPARGC1B is located at 5q33, which has been previously
linked to schizophrenia [44] and PPARGC1B participates
in mitochondrial biogenesis and plays a role in fat oxida-
tion and nonoxidative glucose metabolism [45], which is
interesting in light of evidence of glucose metabolism
abnormalities and mitochondrial dysfunction in schizo-
phrenia. None of the other Diagnosis × Glucose depriva-
tion × Probeset effect genes that passed a step-down FDR
cutoff of 25% is known to play a role in glucose metabo-
lism or to be sensitive to metabolic stressors. Thus, induc-
tion of gene expression changes in vitro by glucose
reduction could be compared to increased glucose con-
centrations which may alter mitochondrial and metabolic
function.
IRF5 expression was down-regulated in cohort 1. We
examined the relationship between Interferon Regulatory
Factor 5 (IRF5) expression and genotype and found
expression of IRF5 to variation at SNP rs10954213 in all
cohorts. However, IRF5 gene expression alteration in LCLs
or brain was not observed in schizophrenia in a larger
sample of subjects by RT-PCR and no SNP association
with schizophrenia was observed.
IPA network analysis of transcripts with significant Diag-
nosis × Glucose deprivation × Probeset effects revealed a
network of 18 genes that showed diagnosis-dependent
expression alterations following glucose deprivation. D-
glucose and hepatocyte nuclear factor 4, alpha (HNF4A)
were two nodes in this gene network. HNF4A mutations
have been associated with type II diabetes [46-48]. This
gene is located at 20q12, a previously identified locus of
schizophrenia [44]. This gene is interesting in light of
findings of increased prevalence of diabetes in schizo-
phrenia [28], and further investigation of HNF4A variants
in schizophrenia may be warranted. IPA network analysis
of transcripts with significant Diagnosis × Probeset effects
revealed a network of 18 down-regulated and four up-reg-
ulated genes. Interestingly, calmodulin, which has previ-
ously been shown to be altered in expression in
schizophrenia [49], was a centrally located complex
within this network. If replicated, genes in these networks
may represent novel targets for further study in schizo-
phrenia.
The results of this study were compared with a recent
study of microarray gene expression in the DLPFC of sub-
jects with schizophrenia and control subjects [50]. Of the
54 genes identified by Maycox et al (2009) [50], there
were 12 genes with diagnosis or Diagnosis × Probeset
effects displaying nominal p-values < 0.05 in the current
study (see Additional file 1). These results indicate that
case and control derived cell lines might be a reliable and
Table 8: The QPCR results showed a significant decrease in brain gene expression of GLS in subjects with schizophrenia compared to 
controls.
Genes BPD
FC
MDD
FC
SZ
FC
BPD versus C p-value MDD versus C p-value SZ versus C p-value
PDE4D 1.08 1.00 0.96 0.42 0.99 0.61
GLS 0.99 0.99 0.73 0.94 0.92 0.04
DSC2 0.99 1.06 0.97 0.93 0.40 0.66
DSC3 0.96 1.00 1.01 0.75 0.98 0.94
ADCY1 0.88 0.87 1.00 0.03 0.00 0.95
No significant alterations of DLPFC gene expression in schizophrenia of any other transcript examined. BPD -- bipolar disorder; C -- control; MDD 
--major depressive disorder; SZ -- schizophrenia; FC -- Fold ChangeBMC Medical Genomics 2009, 2:62 http://www.biomedcentral.com/1755-8794/2/62
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easily maintained resource for the study of the expression
phenotype that is disease associated.
The human transcriptome was recently shown to have
over 90% alternatively spliced variants [51] and it will be
increasingly important to identify those variants at the
exon level that differentiate cases and controls. We have
shown that differential exon usage is associated with case
- control differences, while few transcripts showed a com-
plete differentiation across the entire gene; instead, differ-
ential expression was restricted to specific exons within a
transcript. To fully pursue individual splice variants
requires more validation experiments, but having a profile
across the transcript represents a first approximation.
The use of exon arrays allowed for the possibility of
detecting exon-specific changes in expression [24]. Previ-
ous work has shown a high level of agreement between
digital counts by deep sequencing agreement with exon
array [52]. In identifying gene expression alterations in
LCLs, it may be important to combine theoretically valid
experimental manipulations of cell lines from subjects
with schizophrenia to induce gene expression alterations
relevant to the disorder. An example would be to silence
gene expression through siRNA transfection, and measure
effects on known interactors.
Expression of schizophrenia candidate genes in 
lymphoblastoid cell lines
One aspect of the present work was that many of the top
candidate genes did not exhibit diagnosis or glucose dep-
rivation effects. Although many schizophrenia candidate
genes were expressed above background levels in LCLs,
there was no overlap between the candidate genes identi-
fied in a recent meta-analysis of gene association studies
[53] and genes with significant Diagnosis × Probeset ×
Glucose deprivation effects on expression found in this
study. This may be due to tissue specificity (brain versus
lymphocyte) of gene expression alterations in schizophre-
nia, or due to the selection of the control group, which
consisted of relatives of subjects with schizophrenia and
who likely carry many of the same genetic risk factors as
their affected family members. Alternatively, reactive oxy-
gen species generation might be increased more by
increased glucose utilization [54], as we did not detect an
over representation of mitochondrial or reactive oxygen
genes by lowering glucose concentrations in cells. It is to
be expected that increased glucose concentration would
lead to more alterations in mitochondrial related genes.
A second aim of this study was to identify cis-regulated
alterations in gene expression from the mRNA by SNP
Browser [30] as one criterion for further study in the con-
text of an association with the disease. There was a signif-
icant association between an IRF5 genotype and
expression. A genotype effect of SNP rs10954213 on IRF5
expression was significant in LCLs, and was validated in
the prefrontal cortex and anterior cingulate. However,
there was no significant Diagnosis × Genotype effect on
expression or a significant association of genotype with
diagnosis in a larger sample for rs10954213. IRF5 exhibits
genetically controlled polymorphic transcript variation
[55]. The SNP rs10954213 variant in IRF5 is in the 3'-
untranslated region (UTR) previously shown to influence
IRF5 gene expression [33] in LCLs. This SNP creates a
functional polyadenylation site and the A genotype corre-
lates with increased expression of a transcript variant con-
taining a shorter 3'-UTR [33], which was the same
association found in LCLs, and brain tissue in the present
study.
The 3'-UTR of mRNA has important functions in the sta-
bility, localization, and translation of mRNA [56]. Micro-
RNAs (miRNAs), are small noncoding RNAs that recruit
an argonaute protein complex to a complementary target
mRNA. Each miRNA-Ago complex interacts with a specific
mRNA, typically through pairing of nucleotide bases
between the miRNA sequence and complementary
sequences in the mRNA's 3-untranslated region (3'UTR),
which results in translation repression or degradation of
the mRNA. A miRNA binding site for hsa-miR-185 was
identified 1 bp downstream of SNP rs10954213 using the
web based tool, MicroInspector [57]. It is possible that the
effect of SNP rs10954213 variant on IRF5 protein levels
may be mediated via this shortened 3'-UTR lacking this
miRNA binding site. A further experiment to correlate
reduction in protein expression with genotype would
address this speculation.
We cannot rule out the possible effects of antipsychotics
or cigarette smoking on gene expression. Recent research
suggests that cigarette smoke and antipsychotic treatment
may lead to gene-silencing effects through DNA methyla-
tion changes [58-60] which could lead to long-term
changes in cell lines derived from smokers. The overlap
between genes included in the IPA analysis and those
known to be altered by antipsychotics or nicotine were
assessed with Ingenuity and no overlap was observed.
Conclusion
This study supports the use of experimental manipulation
on LCLs to examine alterations in gene expression at the
exon level in psychiatric disorders [3,61]. These results
support the combined use of exon array, mRNA by SNP
Browser software [30], and genotyping in the identifica-
tion of gene variants that are associated with regulation of
expression in cell lines to find disease specific associa-
tions.BMC Medical Genomics 2009, 2:62 http://www.biomedcentral.com/1755-8794/2/62
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